A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Two Dosages of Paliperidone ER in the Treatment of Patients With Schizoaffective Disorder.

Trial Profile

A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Two Dosages of Paliperidone ER in the Treatment of Patients With Schizoaffective Disorder.

Completed
Phase of Trial: Phase III

Latest Information Update: 26 Jul 2013

At a glance

  • Drugs Paliperidone (Primary)
  • Indications Schizoaffective disorder
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 14 Jun 2012 Actual patient number changed from 314 to 316 as reported by ClinicalTrials.gov.
    • 04 Jan 2011 Janssen Cilag reports that the European Union has approved paliperidone extended-release for the treatment of schizoaffective disorder based on the results of this study.
    • 01 May 2010 Results published in the Journal of Clinical Psychiatry.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top